Group 1 - ARKO Corp. (ARKO) closed at $5.01, with a 14.9% gain over the past four weeks, and a mean price target of $6.63 indicating a 32.3% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $2.21, where the lowest estimate is $4.50 (10.2% decline) and the highest is $9.00 (79.6% increase) [2] - Analysts show strong agreement on ARKO's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ARKO's current year has increased by 112.5%, with one estimate moving higher and no negative revisions [12] - ARKO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of ARKO's potential gain, it does suggest a positive direction for price movement [14]

Group 1 - The stock of a.k.a. Brands (AKA) closed at $11.1, showing a 0.1% gain over the past four weeks, with a mean price target of $20.5 indicating an 84.7% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $11.09, where the lowest estimate is $9.00 (18.9% decline) and the highest is $30.00 (170.3% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 5.3% over the past month, with one estimate rising and no negative revisions [12] - AKA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Hippo Holdings Inc. (HIPO) has seen an 11% increase in share price over the past four weeks, closing at $28.83, with a potential upside of 26.6% based on Wall Street analysts' mean price target of $36.5 [1] Price Targets and Analyst Consensus - The average price target for HIPO ranges from a low of $26.00 to a high of $41.00, with a standard deviation of $7.05, indicating variability in estimates [2] - The lowest estimate suggests a decline of 9.8%, while the highest indicates a potential upside of 42.2% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising HIPO's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 44.2%, with two estimates moving higher and no negative revisions [12] - HIPO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - ACI Worldwide (ACIW) shows potential for significant upside, with a mean price target of $64.6 indicating a 45% increase from the current price of $44.55 [1] Price Targets - The average price target consists of five estimates ranging from a low of $60.00 to a high of $77.00, with a standard deviation of $7.4, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a 34.7% increase, while the highest suggests a 72.8% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about ACIW's earnings prospects, as indicated by a trend of upward revisions in earnings estimates [4][11] - The Zacks Consensus Estimate for the current year has increased by 0.1% due to one upward revision and no negative revisions in the last 30 days [12] Zacks Rank - ACIW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential upside [13] Caution on Price Targets - While price targets are a common metric, they should not be the sole basis for investment decisions due to historical inaccuracies in predicting actual stock price movements [3][7][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]

Group 1 - Remitly Global, Inc. (RELY) closed at $18.95, with a 3.7% gain over the past four weeks, and a mean price target of $27.11 suggests a 43.1% upside potential [1] - The average price target ranges from a low of $21.00 to a high of $32.00, with a standard deviation of $3.48, indicating variability among analysts' estimates [2] - Analysts show strong agreement on RELY's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 11.1% over the past month, with no negative revisions [12] - RELY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1 - Shares of Syndax Pharmaceuticals (SNDX) have increased by 2.2% over the past four weeks, closing at $9.57, with a mean price target of $32.33 indicating a potential upside of 237.8% [1] - The mean estimate consists of 12 short-term price targets with a standard deviation of $10.46, where the lowest estimate of $17.00 suggests a 77.6% increase, and the highest estimate of $45.00 indicates a potential surge of 370.2% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 0.5% over the past month [11][12] Group 2 - SNDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be reliable indicators of actual stock gains, they can provide a directional guide for price movement [14]

Market Trends - Altcoins are experiencing a surge in social media mentions and higher price targets, following Ethereum's lead [1] - Mass retail FOMO (Fear Of Missing Out) initially focused on Bitcoin, then shifted to Ethereum, with price targets exceeding $4,000 [1] Cryptocurrency Focus - The industry is tracking assets for the next significant FOMO spike [1]

Core Viewpoint - Hillman Solutions Corp. (HLMN) has seen a 13.1% increase in share price over the past four weeks, closing at $7.77, with a potential upside of 40.8% based on Wall Street analysts' mean price target of $10.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.54, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting a 3% increase, while the highest estimate is $15.00, indicating a potential surge of 93.1% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][9] Analyst Optimism and Earnings Estimates - Analysts show strong agreement in revising HLMN's earnings estimates upward, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - HLMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - The combination of a positive earnings outlook and a strong Zacks Rank suggests a more conclusive indication of the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of HLMN's potential gains, the direction indicated by these targets appears to be a useful guide for further research [14]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]